Atara Biotherapeutics, Inc.
ATRA
$14.02
$1.4711.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 51.27% | 202.41% | 475.53% | 1,404.02% | 2,111.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.27% | 202.41% | 475.53% | 1,404.02% | 2,111.34% |
| Cost of Revenue | -46.66% | -18.18% | -37.46% | -40.47% | -38.81% |
| Gross Profit | 256.14% | 166.19% | 139.15% | 96.89% | 80.13% |
| SG&A Expenses | -25.63% | -13.31% | -15.18% | -22.63% | -19.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.99% | -26.28% | -20.57% | -25.40% | -24.22% |
| Operating Income | 131.48% | 111.58% | 98.54% | 70.91% | 58.19% |
| Income Before Tax | 117.58% | 103.18% | 93.27% | 69.06% | 54.13% |
| Income Tax Expenses | -33.33% | -306.25% | -311.76% | -180.00% | 200.00% |
| Earnings from Continuing Operations | 117.57% | 103.20% | 93.29% | 69.07% | 54.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 117.57% | 103.20% | 93.29% | 69.07% | 54.12% |
| EBIT | 131.48% | 111.58% | 98.54% | 70.91% | 58.19% |
| EBITDA | 136.53% | 115.30% | 101.04% | 72.29% | 59.30% |
| EPS Basic | 108.67% | 99.00% | 93.03% | 80.29% | 63.01% |
| Normalized Basic EPS | 114.06% | 101.75% | 94.61% | 81.22% | 65.83% |
| EPS Diluted | 108.51% | 98.90% | 92.97% | 80.28% | 63.00% |
| Normalized Diluted EPS | 113.90% | 101.64% | 94.54% | 81.22% | 65.83% |
| Average Basic Shares Outstanding | 100.51% | 102.17% | 90.58% | 76.71% | 40.68% |
| Average Diluted Shares Outstanding | 101.36% | 103.16% | 91.05% | 76.71% | 40.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |